Abbott India
Premium MNC branded franchise (Thyronorm, Udiliv, Duphaston, Cremaffin) with category leadership in GI, thyroid and women's health; cash-rich consistent compounder.
A full research profile for one company — what it does, how its financials have trended, how the market values it, and a balanced bull/bear/base investment memo.
Scan the top row for the headline numbers, read the charts for trends, check the three gauge scores, then read the auto-generated memo at the bottom. Sources for every figure are linked at the very bottom.
- EBITDA
- — Earnings before interest, tax, depreciation & amortisation — a proxy for operating cash profit.
- PAT
- — Profit After Tax — the bottom-line net profit.
- FCF
- — Free Cash Flow — cash left after running the business and capital spending.
- ANDA
- — Abbreviated New Drug Application — the US FDA filing to sell a generic drug.
Revenue
₹ crore · FY
EBITDA
₹ crore · FY
Margins
EBITDA & PAT margin %
R&D Spend
₹ crore · FY
Free Cash Flow
₹ crore · FY
Revenue Mix
By geography / segment
Quality Score
Growth Score
Regulatory Risk
Snapshot
Business Model
How the company makes money
India arm of Abbott: branded chronic (GI, CNS, women's health, metabolics); asset-light, high-ROCE.
Brand-building + price/mix in chronic categories
Pricing/NLEM & limited new-molecule access
Peer Group
Click to compare
| Peer | Rev CAGR | EBITDA% | ROCE | P/E |
|---|---|---|---|---|
| Abbott India | 10% | 26% | 46% | 36x |
| GSK Pharmaceuticals (India) | 8% | 31% | 63% | 38x |
| Pfizer (India) | -4% | 33% | 24.2% | 27x |
| Eris Lifesciences | 14% | 35% | 14% | 31x |
| Torrent Pharmaceuticals | 25% | 32% | 27% | 68x |
Investment Memo
Auto-generated from the data layer — illustrative, not advice
- • Brand-building + price/mix in chronic categories underpins a 10% 5Y revenue CAGR.
- • Premium 26% EBITDA margin with 46% ROCE signals durable economics.
- • Clean balance sheet (D/E 0.00) funds growth internally.
- • Pricing/NLEM & limited new-molecule access.
- • Pricing/NLEM exposure on the domestic book can cap realisation.
- • Valuation at 36x P/E prices in continued execution — little margin for error.
Abbott India screens as a high-quality domestic formulations franchise. With revenue of ₹6.4K Cr growing ~10% and 26% EBITDA margins, the base case is steady compounding driven by brand-building + price/mix in chronic categories, while watching pricing/nlem & limited new-molecule access.
Trades at 36x P/E, 28.0x EV/EBITDA and 11.6x P/B. A premium to the sector — justified only if growth and returns hold.
- 1 India IPM outperformance & chronic mix
- 2 Gross-margin trajectory & new-launch contribution
- 3 R&D productivity (filings/approvals per ₹ of R&D)
- 4 Capital allocation — capex payback & M&A discipline
India-only MNC (standalone), ~100% domestic. High ROE/ROCE (34%/46%), near debt-free; outsources most manufacturing.